Abstract: Systems, apparatuses, and methods for converting computer program source code from a first high level language to a functionally equivalent second high level language different from the first high level language. Source code in a first high level language is analyzed. In response to identifying a derived class in the source code in and determining that the derived class includes more than one base class that includes state information, new source code in the second high level language is generated that includes a class with fields for only one of the base classes that includes state information, separate interfaces in the second high level language that correspond to each base class of the more than one base class other than the one of the base classes that includes state information, and a derived class that corresponds to the derived class in the first high level language. The derived class implements the separate interfaces.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for a touchless testing platform employed to, for example, create automated testing scripts, sequence test cases, and implement determine defect solutions. In one aspect, a method includes the actions of receiving a log file that includes log records generated from a code base; processing the log file through a pattern mining algorithm to determine a usage pattern; generating a graphical representation based on an analysis of the usage pattern; processing the graphical representation through a machine learning algorithm to select a set of test cases from a plurality of test cases for the code base and to assign a priority value to each of the selected test cases; sequencing the set of test cases based on the priority values; and transmitting the sequenced set of test cases to a test execution engine.

Abstract: Techniques for merging versions of an inclusion application that is incorporated in a master application are disclosed. One version of an application may be stored as an application that is incorporated into another application. An application that is incorporated into another application may be referred to as an “inclusion application.” An application incorporating another application may be referred to as a “master application.” Additionally, a different version of the application may be stored as an application that is executed independently, without reference to other applications. A merging engine applies a set of conflict resolution rules to the two versions of the application to obtain a merged version of the application. The merging engine incorporates the merged version of the application in the master application.

Abstract: A microchip comprises a flow pass in which a solution containing particles can flow, and a deflection mechanism for deflecting a portion of the particles as the particles flow through the flow pass.

Abstract: A data storage medium stores string data that can be used in character recognition and instructions for accessing the string data. The string data includes data units that can be accessed by a processor in executing the instructions. The processor can use character data indicating characters of a string to access a sequence of the data units that ends with an ending subsequence. The ending subsequence includes acceptance information indicating whether a string whose sequence of data units ends with the ending subsequence is an acceptable string. If so, the ending subsequence also includes category set information indicating a set of categories for strings whose sequences end with the ending subsequence. The categories can include words, numbers, compound words, and so forth. The acceptance information can include a bit in a character label data unit that includes information indicating the character type of an ending character.

Abstract: Clustered antibiotic biosynthetic genes are employed for improvement of production of the antibiotic in microorganisms and for the isolation of other genes involved in the biosynthesis of the antibiotic. The invention is exemplified with improved production of penicillin in Penicillium chrysogenum, with the isolation of another clustered biosynthetic gene(s) and with the expression of penicillin biosynthetic genes in Acremonium chrysogenum.

Abstract: A human T cell clone containing an integrated copy of HIV in a latent state, but inducible to productive replication by an activating agent is provided. The clone of the present invention allows in vitro screening of anti-HIV drugs.

Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying and isolating additional members of this gene family.

Abstract: Monoclonal antibodies or paratope-containing portions thereof are disclosed that immunoreact with a meso diester substrate ligand and catalytically hydrolyze a single predetermined ester bond to form one of a pair of enantiomers. Methods of making and using the same are also disclosed.

Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.

Abstract: The disclosure describes a method for incorporating into double stranded DNA and RNA base pairs composed of pairing units that fit the Watson-Crick geometry in that they involve a monocyclic six membered ring pairing with a fused bicyclic heterocyclic ring system composed of a five member ring fused with a six membered ring, with the orientation of the heterocycles with respect to each other and with respect to the backbone chain analogous to that found in DNA and RNA, but with a pattern of hydrogen bonds holding the base pair together different from that found in the AT and GC base pairs (a "non-standard base pair").

Abstract: The present disclosure relates to the application of genetic engineering to provide artificial .beta. cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial .beta. cells, grown in liquid culture, with glucose-containing buffers.

Abstract: An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode inhibitors of DNA synthesis. Such inhibitors play a role in cellular senescence and aging. Antisense nucleic acids reduce the inhibition of DNA synthesis.

Abstract: Disclosed are polypeptides which antagonize the activity of platelet-derived growth factor (PDGF). These polypeptides include an amino acid sequence sufficiently duplicative of at least a portion of the amino acid sequence of an A chain of PDGF such that the polypeptides bind a cell membrane-bound receptor for native PDGF on a cell that responds biologically to the binding of PDGF. The binding of the antagonist to the receptor is effective to inhibit PDGF binding and activity. Also disclosed are methods of preparing and using these antagonists.

Abstract: Lymphocytes of NK phenotype were cultured with stimulator cell lines in the presence of growth factor containing medium. The resulting lines and clones derived from these lines expressed CD16 and/or Leu 19, but lacked detectable CD3 or T cell receptor .gamma./.delta. complexes on the cell surface. In addition to displaying potent cytolytic activity against K562 erythroleukemia cells (a classical NK target), the vast majority of these lines and clones lysed their specific stimulator cell lines to a significantly greater extent than irrelevant cell lines. These results indicate that some CD3- lymphocytes, phenotypically indistinguishable from NK cells, can recognize and lyse allogeneic targets in a specific manner.

Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.

Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.

Abstract: The present invention relates, in general, to a method of screening agents. In particular, the present invention relates to a method of testing the cancer preventing activity of a drug and of testing an agent for its ability to prevent cell transformation.

Abstract: Herein described are variants of parathyroid hormone that retain significant PTH activity and are substantially resistant to trypsin and trypsin-like enzymes. The variants are useful pharmaceutically, to treat bone disorders such as osteoporosis and in other therapeutic applications. Specific embodiments of the invention include [His.sup.25 ]PTH and [His.sup.25 His.sup.26 Leu.sup.27 ]PTH.